KR101811736B1 - 렌티바이러스 패키징을 위한 비-서브타입 b gag 단백질의 용도 - Google Patents

렌티바이러스 패키징을 위한 비-서브타입 b gag 단백질의 용도 Download PDF

Info

Publication number
KR101811736B1
KR101811736B1 KR1020147009812A KR20147009812A KR101811736B1 KR 101811736 B1 KR101811736 B1 KR 101811736B1 KR 1020147009812 A KR1020147009812 A KR 1020147009812A KR 20147009812 A KR20147009812 A KR 20147009812A KR 101811736 B1 KR101811736 B1 KR 101811736B1
Authority
KR
South Korea
Prior art keywords
leu
gly
glu
lys
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147009812A
Other languages
English (en)
Korean (ko)
Other versions
KR20140116053A (ko
Inventor
티-란 트랜
피에르 샤르노
세실 보슈
Original Assignee
떼라벡띠스
앵스티띠 파스퇴르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47522726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101811736(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 떼라벡띠스, 앵스티띠 파스퇴르 filed Critical 떼라벡띠스
Publication of KR20140116053A publication Critical patent/KR20140116053A/ko
Application granted granted Critical
Publication of KR101811736B1 publication Critical patent/KR101811736B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020147009812A 2011-09-26 2012-09-25 렌티바이러스 패키징을 위한 비-서브타입 b gag 단백질의 용도 Active KR101811736B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11306222 2011-09-26
EP11306222 2011-09-26
PCT/IB2012/002363 WO2013046034A2 (en) 2011-09-26 2012-09-25 Use of non-subtype b gag proteins for lentiviral packaging

Publications (2)

Publication Number Publication Date
KR20140116053A KR20140116053A (ko) 2014-10-01
KR101811736B1 true KR101811736B1 (ko) 2017-12-22

Family

ID=47522726

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147009812A Active KR101811736B1 (ko) 2011-09-26 2012-09-25 렌티바이러스 패키징을 위한 비-서브타입 b gag 단백질의 용도

Country Status (14)

Country Link
US (2) US9752160B2 (enExample)
EP (1) EP2761011B1 (enExample)
JP (3) JP6495653B2 (enExample)
KR (1) KR101811736B1 (enExample)
CN (2) CN107858375A (enExample)
AU (1) AU2012313960B2 (enExample)
BR (1) BR112014007027A2 (enExample)
CA (2) CA2959867C (enExample)
DK (1) DK2761011T3 (enExample)
ES (1) ES2683820T3 (enExample)
IL (1) IL231666B (enExample)
SG (1) SG11201400987QA (enExample)
WO (1) WO2013046034A2 (enExample)
ZA (1) ZA201401780B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2913854A1 (en) 2013-06-03 2014-12-11 Theravectys Lentiviral vectors containing an mhc class i, mhc class ii, or beta-2 microglobulin upstream promoter sequence
WO2015063706A1 (en) * 2013-10-31 2015-05-07 Theravectys Lentiviral vectors for expression of hiv-1 antigens
EP3009144A1 (en) * 2014-10-15 2016-04-20 Theravectys Lentiviral vectors for inducing CD4+ and CD8+ immune responses in vaccination of humans
WO2016120489A2 (en) * 2015-02-01 2016-08-04 Theravectys Lentiviral vectors for expression of mycobacterium tuberculosis antigens
US12084674B2 (en) * 2019-10-07 2024-09-10 University Of Utah Research Foundation Methods and compositions for a HIV based delivery system
US20250319173A1 (en) * 2021-03-12 2025-10-16 Institut Pasteur Lentiviral vectors targeting antigens to mhc-ii pathway and inducing protective cd8+ and cd4+ t-cell immunity in a host
CN114107393A (zh) 2021-04-07 2022-03-01 上海劲威生物科技有限公司 一种治疗乙型肝炎的慢病毒载体、慢病毒颗粒及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044981A1 (en) * 1999-03-16 2003-03-06 Dana-Farber Cancer Institute, Inc. Pseudotyped lentiviral vectors and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646606B1 (fr) * 1989-05-03 1994-06-17 Inst Nat Sante Rech Med Retrovirus hautement cytopathogenique hiv-ndk. fragment d'adn de ce retrovirus, procede de preparation d'une proteine et/ou enzyme de ce virus et leurs utilisations
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
EP1610816B1 (en) * 2003-03-28 2013-01-02 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Mva virus expressing modified hiv envelope, gag, and pol genes
GB0318704D0 (en) * 2003-08-08 2003-09-10 Sirus Pharmaceuticals Ltd Chimaeric vector system
CA2539021A1 (en) 2003-09-15 2005-03-31 Chiron Corporation Combination approaches for generating immune responses
GB0702694D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Vectors
CN101353667B (zh) * 2008-08-15 2011-06-08 中国人民解放军军事医学科学院微生物流行病研究所 Hiv毒株耐药表型分析细胞模型及其专用假型慢病毒

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044981A1 (en) * 1999-03-16 2003-03-06 Dana-Farber Cancer Institute, Inc. Pseudotyped lentiviral vectors and uses thereof

Also Published As

Publication number Publication date
BR112014007027A2 (pt) 2017-04-11
CA2959867C (en) 2020-04-28
CN107858375A (zh) 2018-03-30
JP2017018132A (ja) 2017-01-26
ES2683820T3 (es) 2018-09-28
IL231666B (en) 2018-03-29
WO2013046034A3 (en) 2013-05-30
WO2013046034A2 (en) 2013-04-04
ZA201401780B (en) 2015-09-30
JP6495653B2 (ja) 2019-04-03
JP2014530000A (ja) 2014-11-17
CN104039968A (zh) 2014-09-10
EP2761011A2 (en) 2014-08-06
AU2012313960A1 (en) 2014-04-10
KR20140116053A (ko) 2014-10-01
US9752160B2 (en) 2017-09-05
AU2012313960B2 (en) 2016-05-12
HK1200870A1 (en) 2015-08-14
JP2018183165A (ja) 2018-11-22
CA2849652A1 (en) 2013-04-04
CA2849652C (en) 2017-11-21
NZ622860A (en) 2016-05-27
EP2761011B1 (en) 2018-05-23
CA2959867A1 (en) 2013-04-04
US20170362607A1 (en) 2017-12-21
IL231666A0 (en) 2014-05-28
US20140234908A1 (en) 2014-08-21
CN104039968B (zh) 2018-10-26
SG11201400987QA (en) 2014-07-30
DK2761011T3 (en) 2018-08-27

Similar Documents

Publication Publication Date Title
US20170362607A1 (en) Use of non-subtype b gag proteins for lentiviral packaging
AU2002303934B2 (en) Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
Di Nunzio et al. HIV-derived vectors for therapy and vaccination against HIV
US5554524A (en) More complex type retroviruses having mixed type LTR, and uses thereof
US20150182617A1 (en) Glycoproteins for pseudotyping lentivectors
AU2002303934A1 (en) Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
WO2012018856A2 (en) Hiv vaccine therapy with concomitant antiviral monotherapy
Mautino et al. Potent inhibition of human immunodeficiency virus type 1 replication by conditionally replicating human immunodeficiency virus-based lentiviral vectors expressing envelope antisense mRNA
JP4627950B2 (ja) 変異ＨＩＶｇａｇ／ｐｏｌ、ＳＩＶｇａｇおよびＳＩＶｅｎｖ遺伝子を持つ分子クローン
Mautino et al. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense
Tung et al. Replication-defective HIV as a vaccine candidate
EP1543837A1 (en) Virus-like particle (VLP) as vaccine
Muratori et al. Inducible expression of the δNGFr/F12Nef fusion protein as a new tool for anti-human immunodeficiency virus type 1 gene therapy
HK1200870B (en) Use of non-subtype b gag proteins for lentiviral packaging
NZ622860B2 (en) Use of non-subtype b gag proteins for lentiviral packaging

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140414

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20141020

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160330

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161228

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20171030

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20171218

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20171219

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20211122

Start annual number: 5

End annual number: 5